Interventional Cardiology Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for interventional cardiology. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)

Condition: 

Stroke

Condition: 

Coronary artery disease, peripheral vascular disease, cancers

Key Inclusion Criteria:

  • At least 18 years old with body mass index less than 30
  • Diagnosed with or undergoing evaluation for cardiovascular, nervous system diseases or solid-organ cancers

Summary:

Using the hybrid Siemens Biograph mMr (PET-MR) scanner, researchers simultaneously acquire MR and PET data across the whole body. Biomedical Imaging Research Institute scientists focus on developing new imaging techniques to answer a wide array of research and clinical questions, where producing a single scan that reveals both functional and anatomical information would create a more complete diagnostic tool. In collaboration with medical specialists, pulse sequences (software) are validated in patients undergoing evaluation for numerous diseases, including many types of heart disease, peripheral and intracranial (brain) neurological diseases, cancers, spine problems, urology and other nervous system disorders. The long-term goal of this study is to develop new techniques that would translate to clinical significance.

Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study (PRELUDE)

Condition: 

Mitral Valve Regurgitation

Condition: 

Cardiac Imaging

Key Inclusion Criteria:

  • Patients undergoing a self-referred or physician-referred cardiac imaging procedure for any standard clinical indication

Summary:

The purpose of this research registry is to develop an organized system of information (demographic, historical, clinical, imaging and outcomes) from patients undergoing cardiac imaging procedures for use in ongoing and future research. The registry will allow qualified investigators at Cedars-Sinai to conduct analyses and write manuscripts that are critical in improving the ability to detect, accurately assess, and possibly prevent adverse outcomes of heart disease.

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT)

Condition: 

Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease (Heart), Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease

Condition: 

Atherosclerotic cardiovascular disease, hypercholesterolemia

Key Inclusion Criteria:

  • Evidence by cardiac computed tomography angiography of noncalcified coronary artery plaque and thoracic aorta atherosclerosis 
  • Indications for evolocumab treatment

Summary:

This study focuses on patients who have clinical atherosclerotic cardiovascular disease (ASCVD) or high cholesterol levels and are allergic to statins, or who have been diagnosed with primary hypercholesterolemia or homozygous familial hypercholesterolemia (genetic disorder causing high cholesterol levels and early heart disease). The purpose of the study is to evaluate the changes, if any, in coronary plaque volumes and its composition in patients who are treated with a drug called evolocumab. To help evaluate the effect of evolocumab, researchers will ask patients who are scheduled to start taking evolocumab plus another cholesterol-lowering medication (such as a statin) to undergo diagnostic testing, including non-invasive coronary computed tomography angiography scans and positron emission tomography (PET) scans.

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Condition: 

Homozygous Familial Hypercholesterolemia

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial (ECLIPSE)

Condition: 

Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction

Evaluation of Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE)

Condition: 

Tricuspid Valve Insufficiency

Condition: 

Aortic stenosis

Key Inclusion Criteria:

  • Severe, calcific aortic stenosis
  • New York Heart Association functional class ≥II
  • At intermediate risk for open surgical therapy

Summary:

The purpose of this study is to evaluate the safety and effectiveness of an investigational device called Edwards CENTERA Transcatheter Heart Valve System (THV)- Model 9551 in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for surgical aortic valve replacement. Aortic stenosis is a critical narrowing of the aortic valve. Participants in this study will have a procedure called transcatheter aortic valve replacement (TAVR) using the CENTERA THV (rather than one of the valves that is usually used for TAVR).

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Condition: 

Homozygous Familial Hypercholesterolemia, HoFH

ILUMIEN IV: OPTIMAL PCI

Condition: 

Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology (PINNACLE FLX)

Condition: 

Atrial Fibrillation

Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Condition: 

Coronary Microvascular Dysfunction

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Condition: 

Hypercholesterolemia

Supporting Patients Undergoing High-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)

Condition: 

Coronary Artery Disease

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation (APOLLO)

Condition: 

Mitral Valve Regurgitation